Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: A review of the clinical trial data and guidelines

Current Medical Research and Opinion

Volumn 23, Issue 6, 2007, Pages 1453-1462

  Hankey, Graeme J ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Antiplatelet; Aspirin; Clopidogrel; Dipyridamole; Secondary prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTACID AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; PROTON PUMP INHIBITOR; TRIFLUSAL;

BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SUSTAINED RELEASE FORMULATION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GUIDELINES AS TOPIC; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLACEBOS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STROKE; VASCULAR DISEASES;

EID: 34347220868     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X199727     Document Type: Review

References (42)

1. World Health Organization (WHO). Global burden of stroke. In: The Atlas of Heart Disease and Stroke. Available from http://www.who.int/ cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf [Last accessed 10 October 2006]
2. Kleindorfer D, Panagos P, Pancioli A, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005;36:720-4
3. Coull AJ, Lovett JK, Rothwell PM, et al. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organization of services. BMJ 2004;328:326
4. Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of transient ischemic attack. JAMA 2000;284:2901-6
5. Hankey GJ. Redefining risks after TIA and minor ischaemic stroke. Lancet 2005;365:2065-6
6. Johnston SC. Transient ischemic attacks are emergencies. Stroke 2005;36:724
7. Brown DL, Lisabeth LD, Roychoudhury C, et al. Recurrent stroke risk is higher than cardiac event risk after initial stroke/transient ischemic attack. Stroke 2005;36:1285-7
8. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic ischemic disease. Stroke 2002;33:909-16
9. Van Wijk I, Kappelle LJ, van Gijn J, et al. Long term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005;365:2098-104
10. Clinical guidelines for stroke rehabilitation and recovery. Available from http://www.strokefoundation.com.au [Last accessed 10 October 2006]
11. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
12. NICE Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events. Available from http://www.nice.org.uk/download.aspx? o=TA090guidance [Last accessed 10 October 2006]
13. Royal College of Physicians. National Clinical Guidelines for Stroke, 2nd edn, 2004. London: Royal College of Physicians. Available from http://www.rcplondon.ac.uk [Last accessed 10 October 2006]
14. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999;66:255
15. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-6
16. Farrell B, Godwin J, Richards S, et al. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54
17. De Schryver ELLM, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD001820. DOI:10.1002/14651858. CD001820.pub2
18. Leonardi-Bee J, Bath PMW, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events. A meta-analysis of individual patient data from randomised controlled trials. Stroke 2005;36:162-8
19. De Schryver ELLM, Algra A, van Gijn J. Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003;34:2072-80
20. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
21. Hankey GJ. Clopidogrel and thrombotic thrombocytopenic purpura. Lancet 2000 22;356:269-270
22. Costa J, Ferro JM, Matias-Guiu J, et al. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004296. DOI:10.1002/14651858.CD004296.pub2
23. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double blind, placebo-controlled trial. Lancet 2004;364:331-7
24. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
25. ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006;367:1665-73
26. Algra A, Van Gijn J, Algra A, et al. Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J Neurol Neurosurg Psychiatry 1999;66:557-9
27. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neuro Sci 1996;143:1-13
28. DGN/DSG Primary and Secondary Prevention of Cerebral Ischaemia. Available from http://www.dgn.org/241.0.html [Last accessed 10 October 2006]
29. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 2006;37:577-617
30. Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23:368-80
31. Gebel JM. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient. J Am Coll Cardiol 2005;46:752-5
32. Gebel JM. Secondary stroke prevention and antiplatelet therapy [letter and author reply]. J Am Coll Cardiol 2006;47:2563-70
33. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
34. Steinhubl SR, Burger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
35. Booze CD, Serebruany VL. The action of dipyridamole to prevent thrombosis: practical implications for the treatment and prevention of stroke. Curr Treat Options Cardiovasc Med 2006;8:221-7
36. Eisert W. How to get from antiplatelet to antithrombotic treatment. Am J Therapeutics 2001;8:443-9
37. Juliano L, Pedersen JZ, Rotilio G, et al. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med 1995;18:239-47
38. Weyrich SM, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 2005;111:633-42
39. Ingerman-Wojenski CM, Silver MJ. Model system to study interaction of platelets with damaged arterial wall. II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719. Exp Mol Pathol 1988;48:116-34
40. Lindgren A, Husted S, Staaf G, et al. Dipyridamole and headache: a pilot study of initial dose titration. J Neurol Sci 2004;223:179-84
41. Chang YJ, Ryu SJ, Lee TH. Dose titration to reduce dipyridamole-related headache. Cerebrovasc Dis 2006;22:258-62
42. Neurology Expert Group. Therapeutic guidelines: neurology. Version 3. Melbourne, Australia: Therapeutic Guidelines Limited; 2007 (April)